Avalo Therapeutics, Inc. - Common Stock AVTX 深 滬
等待開盤 10-25 09:30:00 美东时间
17.7726
-0.147
-0.82%
華盛通- 最 高18.53
- 今 開17.93
- 成交量 33.74万股
- 最 低 17.50
- 昨 收 17.92
- 總市值 1424.67万
- 52周最高 19.41
- 市盈率 靜 --
- 換手率 42.09%
- 52周最低 3.39
- 委 比 27.27%
- 總股本 80.16万
- 歷史最高 22032.00
- 量 比 0.71
- 振 幅 5.75%
- 歷史最低 3.39
- 每 手 1
- 風險率 3.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AVITA Medical Announces CEO Transition
AVITA Medical announces Cary Vance as Interim CEO and Jan Stern Reed as Lead Independent Director following Jim Corbett's departure. The company expects Q3 2025 revenue of ~$17 million and is seeking a permanent CEO, with Vance considered as a candidate.
10-16 22:15
Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation
Avalo Therapeutics ( ($AVTX) ) has shared an update. On October 10, 2025, Avalo...
10-10 19:28
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
Avalo Therapeutics expanded its leadership team by appointing Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President, Human Resources. Boyd brings over 15 years of biotech and corporate finance experience, while Ivanowicz has nearly 20 years of HR expertise in the biotech sector. These additions support Avalo’s mission to advance IL-1β therapies, including its Phase 2 trial for AVTX-009 in hidradenitis suppurativa. Th...
10-01 11:00
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
09-29 17:07
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
ArriVent BioPharma announced the appointment of Brent S. Rice as Chief Commercial Officer. With over 25 years of experience in biotech and pharma, Rice will lead commercial efforts for firmonertinib, a potential treatment for EGFR mutant NSCLC, and advance the company's ADC portfolio. Previously, Rice served as CCO at Autolus Therapeutics and held leadership roles at Amgen and Juno Therapeutics, demonstrating success in launching therapies and bu...
09-22 20:05
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Raises Price Target to $25
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and raises the price target from $15 to $25.
09-17 23:51
Avalo Therapeutics (AVTX) Gets a Buy from Oppenheimer
In a report released today, Leland Gershell from Oppenheimer reiterated a Buy r...
09-15 19:55
Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System
AVITA Medical's study shows that the RECELL® System reduces hospital stays by 36% for adults with deep second-degree burns, saving over $42,000 per patient and improving hospital efficiency. Presented at the 2025 European Burn Association Congress in Berlin, the research highlights RECELL's clinical and economic benefits in modern burn management.
09-04 11:45
Cantor Fitzgerald Initiates Coverage On Avalo Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Overweight rating.
08-15 20:55
